What Is Acute Mountain Sickness (AMS)?

Acute mountain sickness is the most common high-altitude illness encountered on Kilimanjaro and in high-altitude environments worldwide. It typically develops above 2,500–3,000 metres when the body has not yet adapted to the significantly lower partial pressure of oxygen in the air. At Uhuru Peak — Kilimanjaro’s summit at 5,895 m — there is roughly 47% of the oxygen available at sea level. The body works hard to compensate, but for many climbers that compensation is incomplete, especially when ascent is too rapid. This is one of the core Kilimanjaro AMS risk factors every climber should understand before booking a route.

Core AMS symptoms are a headache in the context of a recent altitude gain, plus one or more of: nausea or vomiting, profound fatigue or weakness, dizziness or lightheadedness, and difficulty sleeping. In more severe cases — particularly High Altitude Cerebral Edema (HACE) — symptoms progress to confusion, loss of coordination, and altered consciousness. This is a medical emergency requiring immediate descent.

The Lake Louise Scoring System

Guides and wilderness physicians use the Lake Louise Scoring System (LLSS) to grade AMS severity. The LLSS assigns points across four symptom domains:

A total score of 3–5 indicates mild AMS — rest at current altitude and careful monitoring. A score of 6 or above indicates moderate-to-severe AMS — descent is required. Any neurological signs (confusion, ataxia) indicate possible HACE — descend immediately regardless of score. Our guide on climbing Kilimanjaro with medical conditions covers when pre-existing conditions change this calculus.

On Kilimanjaro, altitude sickness risk increases sharply above Lava Tower Camp (4,630 m), through Barafu Camp (4,673 m), and most critically during summit night when climbers push from 4,673 m to 5,895 m in darkness. Understanding the Lake Louise criteria is not just for doctors — it is essential knowledge for every climber and their guide.

What Peer-Reviewed Research Actually Shows About Gender and Altitude Sickness

The question of whether sex-based differences in hypoxia tolerance exist has been studied for decades. The answer from the literature is — frustratingly — “it’s complicated.” Here is what the best available evidence actually shows.

The 2019 Meta-Analysis: The Strongest Single Study

The most statistically powerful study on AMS gender differences is a 2019 meta-analysis by Hou and colleagues, published in Military Medical Research. It pooled data from 18 prospective studies involving 7,669 participants (2,639 women and 5,030 men) across a range of altitudes and ascent profiles.

Key finding: Women had a statistically higher prevalence of AMS — relative risk 1.24 (95% confidence interval 1.09–1.41). Put in plain language: across these studies, women were roughly 24% more likely to meet the diagnostic threshold for AMS than men in the same conditions.

However, the authors themselves caution that heterogeneity across the included studies was significant. Different altitude thresholds, different ascent rates, different proportions of acetazolamide users, and different diagnostic criteria make direct comparison imperfect. Importantly, no study has established a causal biological mechanism for sex differences in AMS after controlling for confounders like age, BMI, smoking history, and prior acclimatisation — the association is real in aggregate data, but the “why” remains unresolved.

Earlier Research: Mixed and Contradictory

The current StatPearls entry on Acute Mountain Sickness (2025) reflects this mixed picture, concluding that sex is one of many variables and individual physiological response remains the dominant predictor. The Wilderness Medical Society guidelines similarly do not recommend gender-specific management protocols.

Evidence Snapshot: Research vs. Field Observation

What I’ve Observed Over 22 Years of Guiding: Field Notes from the Mountain

In my decades on this mountain I have guided more than 300 summit attempts across every major route. I want to be precise about something before I share what I have seen: my observations are field notes, not clinical trials. I do not have a control group. I may be subject to confirmation bias. I say this because honesty matters more to me than telling a clean story.

Here is the pattern I have watched build slowly, consistently, over hundreds of mixed-gender climbs: when a group crosses above 4,000 metres and symptoms begin, it is more often the male climbers who push through without saying anything, and more often the female climbers who report early and accurately.

I am not presenting these cases, or the internal log summary above, as proof of anything about biology. What they illustrate is a behavioural pattern with practical consequences on the mountain, regardless of its cause.

Beyond Biology: Three Alternative Explanations for the Field Pattern

1. Reporting Bias: The “Toughing It Out” Problem

Some climbers — in my experience, disproportionately male — are socially conditioned to minimise symptoms, avoid appearing weak, or refrain from slowing the group. AMS symptoms disclosed early are manageable; the same symptoms hidden for 12–24 hours can escalate into a situation requiring emergency descent. I now conduct individual, private symptom checks with every climber above 4,000 m, rather than group check-ins where social dynamics suppress disclosure.

2. Muscle Mass and Resting Oxygen Demand

On average, male climbers carry significantly more skeletal muscle mass than female climbers of similar body weight. Muscle tissue at rest demands oxygen, and at altitude — where oxygen partial pressure is already reduced — higher resting oxygen demand can compound acclimatisation stress. Cardiovascular fitness appears more protective than muscular size when it comes to altitude-induced hypoxia and AMS risk.

3. Hydration Discipline

Over hundreds of expeditions, I have observed a consistent difference in hydration discipline: female climbers more often follow hydration guidelines consistently throughout the day. Dehydration at altitude worsens AMS symptoms and accelerates their onset. Drink three to four litres of water daily above 3,000 m, whether or not you feel thirsty — thirst at altitude is a lagging indicator.

The Hormonal Factor — What Science Doesn’t Yet Know

Progesterone, which rises in the luteal phase of the menstrual cycle, is a respiratory stimulant — it increases ventilation at rest. Some laboratory studies, including Wagner et al. (2000), showed women in the luteal phase had modestly better ventilatory responses under hypoxic conditions. Estrogen has also been proposed to have neuroprotective properties relevant to HACE.

However, effect sizes are small, intra-individual variation is large, and the altitude medicine community has not translated this into clinical recommendations. The UIAA Medical Commission does not recommend timing a climb around menstrual cycle phase, and neither do I. This is exactly why fixed gender rules are unhelpful and why individual assessment matters.

Why the Guide Observation and the Research Can Both Be True

Research measures diagnosed AMS — a Lake Louise score above threshold, assessed in a structured study protocol. Guides see the daily expression of symptoms and the lag between onset and disclosure. A male climber who has hidden a Lake Louise 3 headache for 18 hours and finally discloses it at score 6 looks like he is struggling far more than a woman who reported at score 2 the previous afternoon and recovered — even though research would count both as AMS.

Both observations can be accurate simultaneously. The better questions are: who reports early, who paces well, and who trusts their guide? Those are the variables that determine summit outcomes.

Practical Advice for Every Climber, Regardless of Gender

Report Every Symptom Early

A headache at Lake Louise 1 reported immediately is manageable. The same headache hidden until it reaches Lake Louise 5 may end your climb. I conduct individual private check-ins with every climber above 4,000 m precisely because group dynamics suppress honest disclosure.

Do Not Rely on Fitness

Aerobic fitness does not protect you from acute mountain sickness — one of the most important facts to internalise when asking does fitness prevent altitude sickness. Kilimanjaro altitude sickness risk factors are dominated by ascent rate and individual physiological sensitivity, not VO2 max.

Pace to the Most Vulnerable Member

In any group, pace should be set by the person having the hardest day — not the fittest, not the most eager. A guide-led pace is not a compromise; it is a strategy.

Know the Descent Thresholds

Descend without debate if you experience confusion, severe shortness of breath at rest, inability to walk in a straight line (ataxia), a severe headache unresponsive to rest and hydration, or any rapidly worsening symptom. These are non-negotiable descent criteria.

Discuss Acetazolamide (Diamox) With Your Doctor

Acetazolamide (Diamox) can meaningfully reduce AMS risk. The standard prophylactic dose is 125–250 mg twice daily, starting 24–48 hours before major ascent. It has contraindications (sulfa drug allergy; kidney conditions) and side effects (increased urination; tingling in fingers and toes). Our guide on climbing Kilimanjaro with medical conditions covers questions worth asking your doctor before you fly.

Prevention Strategies That Work for Everyone

Choose a Route With Sufficient Days

A 5-day route has a dramatically lower summit success rate than an 8-day route — not because of distance, but because of acclimatisation time. See our full Kilimanjaro Routes comparison.

Climb High, Sleep Low

The Lemosho and Machame routes include a built-in acclimatisation day at Lava Tower (4,630 m) followed by a descent to Barranco Camp (3,960 m) — a principle proven to improve physiological adaptation.

Stay Hydrated and Maintain Nutrition

Three to four litres of water daily above 3,000 m. Eat at every meal even if appetite has dropped, especially carbohydrates.

Avoid Alcohol and Sleeping Tablets

Both suppress breathing during sleep, worsening overnight oxygen desaturation — already impaired at altitude.

Train Appropriately Beforehand

Fitness doesn’t prevent AMS, but it reduces general fatigue that can mask symptoms. Our 12-week Kilimanjaro training guide is the most practical preparation resource we have produced.

Choose the Right Route for Your Group

See our full Kilimanjaro Routes 2026 comparison.

Frequently Asked Questions About Gender and Altitude Sickness

Conclusion: What the Mountain Actually Cares About

After 22 years and more than 300 summit attempts, here is what I know with confidence: the research suggests women may develop AMS slightly more often, while the field pattern I observe is that male climbers more often delay reporting symptoms. Both can be true simultaneously.

What the mountain does not care about is your gender, your fitness level, or how much you spent getting here. It responds to how honestly you communicate, how faithfully you follow your guide’s pace, and how promptly you disclose every symptom.

If you are planning a climb and want advice tailored to who is in your group, that is exactly the conversation I want to have with you before you arrive.

“On Kilimanjaro, the mountain does not care about your gender — it cares about your honesty, your hydration, and your humility.”

We Walk With You.
— Sabinus Msimba, Senior Guide & Co-founder, Kilimania Adventure